Divislab Management Guidance Tracker

Management expects EBITDA margins to stabilize in the 35-40% range over the long term, excluding COVID-related distortions.

Management anticipates double-digit revenue growth going forward, driven by custom synthesis, contrast media, and Sartans.

Management expects double-digit revenue growth for FY25, driven by custom synthesis ramp-up and new generic launches.

Management reiterated confidence in achieving double-digit growth for the full year, driven by both generics and custom synthesis.

Management targets double-digit revenue growth on a yearly basis, driven by custom synthesis and generics.

Management expects overall revenue to grow at a double-digit rate in FY26, driven by custom synthesis and generics.

Three dedicated custom synthesis projects are at various stages of validation/construction and are expected to contribute revenue within 1-2 years, subject to regulatory approvals.

Management expects constant currency revenue growth for the second half to be similar to H1's 10.79%.

Three custom synthesis molecules currently in validation/regulatory approval stages are expected to start commercial volumes in the second half of calendar year 2027.

The Unit III project in Kakinada, with an initial investment of INR 1,500 crore, is expected to start commercial production by mid-2025.

Phase one of the 200-acre greenfield project at Kakinada is progressing and expected to commence production towards the end of Q1 FY2024-25.

Phase I of Kakinada greenfield project will commence production in Q2 FY25, with commercial supplies expected by Q3 FY25 subject to regulatory approvals.

The 200-acre phase I of the greenfield expansion will start production during FY2024-25, with regulatory approvals and customer filings taking 1-2 years for full commercialization.

Phase-wise production at the 200-acre greenfield Kakinada facility will begin in December 2024, initially focusing on backward integration and regulatory qualifications.

The remaining part of Phase I at Kakinada is expected to be operational in about six months.

Validation for some MRI contrast media products is expected to be completed by the end of the current financial year, enabling customer sampling.

Two large custom synthesis projects are now at full production capacity, with revenue contribution expected to be visible in the next quarters.

Revenue from GLP-1 agonist peptide building blocks is expected to start in FY25, with larger volumes thereafter.

Gadolinium-based contrast media process is in final stages; customer approvals and supplies are expected more towards FY25.

Qualifications for GLP-1 building blocks with innovators are ongoing; commercial revenues expected from 2025.

Emerging generic products with DMF filings planned for completion in the next few months will be commercialized in FY2026, targeting patent expiries in 2025-27.

Management expects year-on-year volume increase of 20-30% in contrast media, driven by long-term contracts and new qualifications.

Multiple generic products are advancing towards customer qualifications and regulatory approvals, with revenue contributions expected from 2026.

The company aims for a balanced revenue mix of 50% generics and 50% custom synthesis over time.

The two long-term custom synthesis contracts announced are expected to start commercial production around Q3/Q4 2026 or early 2027, subject to regulatory approvals.

Three custom synthesis projects are underway with long-term supply commitments, expected to commercialize over the next 12-24 months.

Solid-phase peptide synthesis capacity is expected to commercialize within 12-14 months, subject to regulatory approvals and customer timelines.

Management reiterated expectation of double-digit constant currency growth, supported by a balanced pipeline across patent phases.

Management guided maintenance capex in the range of INR 250-300 crore for the current fiscal year.

Total capital expenditure for FY25, including Kakinada, is expected to be around INR 1,600 crores, with INR 1,000 crores remaining to be spent.

Phase I of Kakinada will require about ₹200 crore more in capex, with benefits expected to flow from FY26 onwards.

Management guided for total capital expenditure of INR 2,000 crore in FY26, directed at strategic projects, capacity expansion, and technology upgrades.

Management confirmed that FY26 CapEx will be higher than the earlier guidance of INR 2,000 crore, driven by three new projects with long-term supply commitments.

Company is evaluating a second phase expansion at Unit 3 with 4 additional production blocks, but no final decision or timeline announced.